Is HeartSciences Inc. (HSCS) a Buy, Sell, or Hold?
NASDAQ : HSCS
HeartSciences Inc.
$2.43 USD
-$0.13 (-5.08%)
- Volume
- 17.25K
- Average Volume
- 2.34M
- Market Capitalization
- $5.27M
- P/E Ratio
- -0.61
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $4.30
- Year Low
- $1.63
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.00
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Andrew Simpson |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | HSCS |
| CUSIP | 42254E302 |
| CIK | 0001468492 |
| Web | https://heartsciences.com |
| Phone | 682 237 7781 |
| Currency | USD |
| Employees | 15 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.46 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.00 |
| Quick Ratio | -152.97 |
| Cash Ratio | 795.76 |
Sales & Book Value
| Annual Sales | $89.5M |
| Price / Sales | 0.06 |
| Cash Flow | 2.92 |
| Price / Cash Flow | 0.57 |
| Price / Book | 2.90 |
Price Target and Rating
| Average Stock Price Forecast | $3.00 |
| High Stock Price Forecast | $3.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -19.00% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0 |
| Trailing P/E Ratio | -0.61 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$12.68M |
| Net Margin | -14.16% |
| Pretax Margin | -18.28% |
| Return on Equity | -498.03% |
| Return on Assets | -167.79% |
Financials Score
| AltmanZ Score | -9.91 |
| Piotroski Score | 4.00 |
| Working Capital | 7.72K |
| Total Assets | 7.55M |
| Ebit | -16.36M |
| Market Cap | 5.55M |
| Total Liabilities | 4.9M |
Poll Results
About HeartSciences Inc. (NASDAQ:HSCS) Stock
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartScien ... ces Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
2026-06-23 07:30:00
FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences”), an AI-powered medical technology company, today announced that they have entered into a definitive merger agreement to combine in an all-stock transaction (the “Proposed Transaction”) which is expected to close in H2 2026. Upon closing, the combined company will operate under the Fortitud.
2026-06-11 08:30:00
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function
2026-06-02 08:30:00
Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy
2026-05-19 08:30:00
Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
2026-05-05 09:00:00
Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College of Cardiology Annual Scientific Session Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College of Cardiology Annual Scientific Session
Analyzing Rennova Health (OTCMKTS:RNVA) & HeartSciences (NASDAQ:HSCS)
2026-04-27 02:06:59
Rennova Health (OTCMKTS:RNVA - Get Free Report) and HeartSciences (NASDAQ: HSCS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends. Analyst Recommendations This is a breakdown of recent
Frequently Asked Questions
-
What is the current HeartSciences Inc. (HSCS) stock price?
-
HeartSciences Inc.(NASDAQ:HSCS) stock price is $2.43 in the last trading session. During the trading session, HSCS stock reached the peak price of $4.3 while $1.63 was the lowest point it dropped to. The percentage change in HSCS stock occurred in the recent session was --5.08% while the dollar amount for the price change in HSCS stock was -$0.13.
-
HSCS's industry and sector of operation?
-
The NASDAQ listed HSCS is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of HSCS?
-
Danielle Watson | Chief Financial Officer & Treasurer
Andrew Simpson | Chief Executive Officer, President & Chairman of the Board of Directors
|
|
| -
How many employees does HSCS have?
-
Number of HSCS employees currently stands at 15. HSCS operates from 550 Reserve Street, Southlake, TX 76092-1552, US.
-
Link for HSCS official website?
-
Official Website of HSCS is: https://heartsciences.com
-
How do I contact HSCS?
-
HSCS could be contacted at phone #682 237 7781 and can also be accessed through its website. HSCS operates from 550 Reserve Street, Southlake, TX 76092-1552, US.
-
How many shares of HSCS are traded daily?
-
The average number of HSCS shares traded daily for last 3 months was 2.34M.
-
What is the market cap of HSCS currently?
-
The market value of HSCS currently stands at $5.27M with its latest stock price at $2.43